US 12,331,079 B2
Oncolytic virus platform to treat cancers with myxoma virus
Douglas Grant McFadden, Tempe, AZ (US); Mohammed Masmudur Rahman, Chandler, AZ (US); Nancy Villa, Tempe, AZ (US); Lino Torres-Dominguez, Tempe, AZ (US); Lina Franco Achury, Tempe, AZ (US); and Leslie Lynne Sharp, Rancho Santa Fe, CA (US)
Assigned to Arizona Board of Regents on behalf of Arizona State University, Scottsdale, AZ (US)
Filed by Arizona Board of Regents on behalf of Arizona State University, Scottsdale, AZ (US)
Filed on Aug. 22, 2022, as Appl. No. 17/893,052.
Application 17/893,052 is a continuation of application No. 17/357,624, filed on Jun. 24, 2021, abandoned.
Application 17/357,624 is a continuation of application No. 17/010,711, filed on Sep. 2, 2020, granted, now 11,117,934, issued on Sep. 14, 2021.
Claims priority of provisional application 62/944,233, filed on Dec. 5, 2019.
Claims priority of provisional application 62/894,925, filed on Sep. 2, 2019.
Prior Publication US 2023/0025706 A1, Jan. 26, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/065 (2006.01); A61K 39/275 (2006.01); A61K 45/06 (2006.01); A61P 35/04 (2006.01); C07K 14/005 (2006.01); C07K 14/525 (2006.01); C07K 14/54 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01)
CPC C07K 14/005 (2013.01) [A61K 39/275 (2013.01); A61K 45/06 (2013.01); A61P 35/04 (2018.01); C07K 14/525 (2013.01); C07K 14/5434 (2013.01); C12N 7/00 (2013.01); A61K 2039/5154 (2013.01); A61K 2039/5256 (2013.01); A61K 2039/545 (2013.01); A61K 2039/572 (2013.01); A61K 2039/585 (2013.01); C07K 2319/33 (2013.01); C12N 2710/24022 (2013.01); C12N 2710/24033 (2013.01); C12N 2710/24071 (2013.01)] 20 Claims
 
1. A pharmaceutical composition comprising:
i) a myxoma virus (MYXV) comprising a genetic modification at its M153 locus and a transgene encoding a cytokine or a cell matrix protein; and
ii) a pharmaceutically acceptable excipient.